Last edition
News about "IDEFIRIX licensing agreement"
Hansa Biopharma Signs IDEFIRIX Licensing Deal with SERB Pharmaceuticals for Europe and MENA
Hansa Biopharma signs a €115 million licensing agreement with SERB Pharmaceuticals for commercialisation of IDEFIRIX across Europe and MENA, strengthening its financial position ahead of a potential US launch.
IDEFIRIX Licensing Agreement | 21/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members